

# A REVIEW ON THE IMPORTANCE OF HAEMATOLOGICAL MARKERS IN RELATION TO TYPE 2 DIABETES MONITORING

## ABSTRACT

Diabetes mellitus is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin that it produces. The most common type of diabetes is type II diabetes, which is characterized by insulin resistance or relative insulin deficiency. Diabetes mellitus shows a significant derangement in various hematological parameters, including changes affecting red blood cells.

Complete blood counts (CBCs) are a useful tool for monitoring a patient's diabetes control and for identifying potential CBC parameter changes that could be signs of diabetes mellitus detection and management. The main cause of both micro and macrovascular complications in diabetic patients is inadequate control of their blood sugar levels. Regular exposure to red cell hyperglycemia causes the haemoglobin protein to continuously glycosylated, altering the molecule's structure and function. Along with protein glycation, hyperglycemia affects red blood cells in other ways as well. These include altered mechanical characteristics, increased aggregation, and osmotic fragility, which alter erythrocyte structure and the hemodynamic process.

This research evaluates the predictive power of red blood cell characteristics for glycemic management in individuals with type 2 diabetes.

The aim of this study is to investigate the alterations in haematological parameters during diabetes mellitus.

**Comment [1]:** This is research study or only review article? It is not yet clear

*Keywords: Diabetes Mellitus, HBA1C- Glycated Hemoglobin, Hyper Glycemic Index, RBC Indices*

## ABBREVIATIONS

<b>CBC:</b>	<i>Complete Blood Count</i>
<b>T2DM:</b>	<i>Type2 Diabetic Mellitus</i>
<b>FBS:</b>	<i>Fasting Blood Sugar</i>
<b>RBS:</b>	<i>Random Blood Sugar</i>
<b>OGTT:</b>	<i>Oral Glucose Tolerance Test</i>
<b>MCV:</b>	<i>Mean Corpuscular Volume</i>
<b>MCH:</b>	<i>Mean Corpuscular Hemoglobin</i>
<b>MCHC:</b>	<i>Mean Corpuscular Hemoglobin Concentration</i>
<b>RDW:</b>	<i>Red cell Distribution Width</i>

## 1. INTRODUCTION

Diabetes mellitus is a chronic disease associated with the inability to produce an adequate amount of hormone insulin or to effectively use the insulin

produced by the body [1]. It is a diverse set of disorders defined by different abnormalities in the control of protein, lipid, or carbohydrate metabolism [2]. Uncontrolled blood glucose levels have been associated with a number of conditions that can cause disability, such as cardiovascular disease, nerve damage that can result in different types of neuropathies and kidney damage that can lead to diabetic nephropathy, diabetic foot that can cause a drop in body temperature, and ocular diseases that primarily affect the retina and cause blindness and vision loss [3].

Long-term exposure to high glucose causes hemoglobin to be glycosylated by enzymes, and membrane proteins cause the aging of red blood cells, which may eventually cause hyperlipemia with a lower red blood cell count. A different process might result from a change in the fluid electrolyte balance. In T2DM patients with high

blood glucose, the activity of the erythrocyte membrane cation pump protein is impaired [4].

The most widely used laboratory tests for screening and tracking blood glucose levels are HbA1C, OGTT, and FBS [5]. The hemoglobin variants known as HbA1C develop when the glucose molecule condenses and attaches itself to the beta chain of hemoglobin's N-terminus amino acid. The HbA1C blood test indicates a patient's average blood glucose level during the previous two to three months, or the predicted life span of red blood cells [6]. The best use of HbA1C as a biomarker is for long-term blood glucose monitoring. In contrast to other glucose-based tests, it is not as affected by variables like dietary consumption, stress levels, physical activity, and immediate treatment response [7].

A complete blood count consists of a panel of tests that are typically used to differentiate between various forms of anemia. RBC parameters include MCV, MCH, MCHC, RDW, hemoglobin, hematocrit, and red blood cell count [8]. One potential cause of elevated RDW in T2DM patients could be hyperglycemia-induced oxidative damage and chronic inflammation. A high intracellular glucose concentration brought on by an influx of glucose to the erythrocyte via the insulin-dependent glucose transporter (GLUT1) may be the cause of an increased MCV in patients with poor glycemic control. This rapid diffusion of water into the cell flattens the biconcave disk and bloats the cell [8, 9].

Even though HBA1C is still the gold standard for evaluating long-term glycemic management, poor nations have limited access due to the high cost of this test when it comes to routine diagnostic care [10]. Red cell characteristics that can be utilized to track the course of complications and diabetes control are the primary focus of this review. Thereby making them a valuable tool for the assessment of T2DM patients [11].

Ultimately, our efforts have been limited assess of HBA1C testing seems to be a key marker of inadequate glycemic control in T2DM patients as well as a major obstacle to improving glycemic control. HBA1C testing is relatively expensive in certain private sectors and is not easily accessible in public health faculties in rural areas of developing nations like India. Thus, in nations with limited resources, a widely available instrument for tracking glycemic status is required. Therefore, the goal of the study is to assess red blood cell

characteristics for monitoring type 2 diabetes patients. Our findings may help with T2DM management in the future.

## 2.INSULIN RESISTANT DIABETES MELLITTUS

Diabetes mellitus is a type of metabolic disease characterized by elevated blood sugar levels, which are typically caused by abnormalities in insulin secretion, flow, or both. Because of hyperinsulinemia, the body's cells and tissues are not receiving enough insulin, which leads to irregularities in the metabolism of fat, protein, and carbohydrates. Insulin-dependent diabetes mellitus (type 1) and non-insulin-dependent diabetes mellitus (type 2) are the two main forms of diabetes. Reduced insulin secretion will prevent glucose from entering the cell, which will cause hyperglycemia. It is possible for insulin to reduce hyperglycemia [13].

Type 2 diabetes mellitus is the most prevalent type of disease in adults. It is a long-term metabolic illness characterized by low insulin synthesis or insulin resistance, both of which raise blood sugar levels [14]. Chronic hyperglycemia causes a number of physiological and pathological processes, such as oxidative stress, which impacts lipid metabolism, inflammatory response, cell growth, immunological, and hematological parameters, all of which are evident in patients with poorly controlled diabetes [15]. Increased oxidative stress causes hematological changes that impact platelets, WBCs, and RBCs in terms of their structure, function, and metabolism [16].

The primary cause of end-stage renal disease is diabetes mellitus, and a significant number of patients with diabetes mellitus experience renal complications [17].

Diabetes patients experience anemia twice as frequently as non-diabetics. When comparing individuals with diabetes nephropathy to those with nephropathy from other causes, the risk of anemia is increased [18]. Chronic hyperglycemia associated with diabetes may cause a hypoxic environment in the renal interstitium, which will reduce erythropoietin synthesis.

An increased leukocyte count relates to the presence of neuropathy and vasculopathy [19].

Comment [2]: Should be "mellitus"

Comment [3]: What is the explanation

The autoimmune response that results in the body's defense system attacking the beta cells in the pancreas that produce insulin is the cause of type 1 diabetes mellitus. The body can no longer create insulin as a result [20].

It's crucial to remember that patients with diabetes are more atherogenic from dyslipidemia than people without the disease. Dyslipidemia, hypertension, and altered hematological indicators are all components of the metabolic syndrome, which includes type 2 diabetes [21].

### 3.ASSESSMENT OF GLYCEMIC INDEX

In patients with diabetes, inadequate management of their blood sugar levels is a major risk factor for the development of micro and macrovascular complications [22]. In diabetes, microvascular complications are the main cause of death rather than cardiovascular disease [23]. The disease known as atherosclerosis is inflammatory. Nearly every blood component, including platelets, WBCs and RBCs has a part in the underlying pathophysiology of atherosclerosis [24].

It's critical to achieve HbA1C range optimization of 6.5–7% [25]. Glycated protein, urine sugar, fructosamine, glycated hemoglobin (HbA1C), urine protein such as micro albuminuria, glucose level in plasma (random sample), and urine sugar are among the laboratory tests used to monitor patients with diabetes mellitus [26].

HbA1C is the glycemic range for the previous two to three months in individuals with diabetes. One can estimate the mean quantity of glucose based on the HbA1C level [27, 28, 29].

At first, HbA1C was thought to be an abnormal hemoglobin in diabetic patients [30]. The extremely porous erythrocyte cell membrane allows hemoglobin to be exposed to higher intracellular glucose levels during hyperglycemia. The non-enzymatic glycation of valine at the n-terminal of the hemoglobin beta-chain results in the formation of glucohaemos. [31]. Increased HbA1C is positively related to the longer duration of type 2 diabetes [32].

Diabetes patients may experience hypertension and vascular illness as a result of high levels of glycated hemoglobin, which have been demonstrated to impair endothelium-mediated vasoactive response [33]. The cytoplasmic

viscosity of the red blood cell, osmotic disruption, and structural and functional alterations in the hemoglobin molecule can all be linked to delayed glycosylation. Any one or all of the red cell analytical measures, including Hb, RBC count, HCT, MCV, and MCHC, may show these alterations. Red cell indices can track the course of a diabetic patient's disease since microvascular complications are linked to elevated HbA1C, changes in red cell deformability, and other hemorheological alterations [34].

Erythrocytes typically live 117 days in men and 106 days in women. Erythrocytes with varied ages and degrees of hyperglycemia exposure are present in the blood sample. Although younger erythrocytes are more numerous, older erythrocytes are probably more exposed to hyperglycemia [35, 36]. Numerous hematologic, genetic, and illness-related variables influence HbA1C [37, 38].

### 4.ASSOCIATION OF BLOOD CELL PARAMETERS IN DIABETES MELLITUS

The complete blood count, which consists of a panel of analytical tests typically used to distinguish between various types of anemia, includes RBC characteristics [39]. The metrics associated with red blood cells are as follows: the number of red blood cells, the hematocrit, the hemoglobin, the mean corpuscular volume, the mean corpuscular hemoglobin concentration, and the red cell distribution width [40].

Many studies have shown a relationship of RBC indices and HbA1C [41, 42].

While mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration characterize the hemoglobin content of RBC, mean corpuscular volume shows the size of RBC [43]. Hyperglycemia affects red blood cell aggregation and deformability and shortens its lifespan [44].

Several hematological changes affect red blood cells, white blood cells and coagulation factors that are shown to be directly associated with diabetes mellitus. Other hematological abnormalities reported in diabetes patients include RBC, WBC, and platelet dysfunction. RDW is a measurement of size variation among circulating red cells and is calculated as part of routine CBC. The RDW along with mean cell volume, is useful in the differential diagnosis of anemia [45].

**Comment [4]:** What the correlation of this statement

Type 2 diabetes mellitus is a fundamental public health problem that has been increasing dramatically worldwide [46]. Inappropriate control of blood glucose in diabetes patients is the main key to the incidence of both micro and macrovascular problems [47].

Hemoglobin and diabetes profiles are closely related. Blood viscosity is also significantly influenced by hemoglobin levels. Blood platelets are essential to the process of blood coagulation. There have been reports of altered platelet shape and function in diabetes patients [48].

Glycation of hemoglobin and membrane proteins causes persistent hyperglycemia in diabetes, which is linked to metabolic, structural, and functional alterations in red blood cells. Moreover, endothelial tissue damage and RBC malfunction are linked to elevated levels of oxygen free radical generation and chronic inflammation [49]. In addition, RBC glycation causes increased aggregation and decreased deformities because it decreases membrane fluidity [50].

#### 4. CONCLUSION

Haematological alterations during diabetes can lead to long-term complications, a poor quality of life, and even death. According to the current study's findings, anemia is more likely to occur in diabetic individuals with inadequate control. The CBC is a standard, easy test that provides significant results. A low-cost method for monitoring patients with type 2 diabetes is the CBC. These measures may be an early sign of the onset of anemia. This suggests that regular CBC examinations are necessary for the early identification and treatment of anemia in diabetes patients in primary care settings. This will help decrease the associated morbidity caused by impaired immunity related to anemia and complications such as diabetic ketoacidosis.

#### CONSENT

It is not applicable

#### ETHICAL APPROVAL (WHERE EVER APPLICABLE)

It is not applicable

#### REFERENCES

1. Meshesha M, Melke A, Ajema A, Mayisso K. Evaluation of Red Blood Cell Indices for Prediction of Glycemic Control in People Living with Type 2 Diabetes. *Diabetes, Metabolic Syndrome and Obesity* . 2024 Feb 1;Volume 17:619–32.
2. Marcovecchio L. Complications of acute and chronic hyperglycemia. *US Endocrinol*. 2017;13(1):17–21.doi: 10.17925/use.2017.13.01.17
3. Kumari N, Singh JK, Prasad K. Assessment of red blood cell parameters as a biomarker for glycaemic control in patients of Type 2 Diabetic mellitus: a Cross-Sectional Study. *International Journal of Pharmaceutical Sciences Review and Research* . 2023 Apr 1;79(2).
4. M A, T S, K K, M FB, M T, B Z. Evaluation of red blood cell parameters as a biomarker for Long-Term Glycemic Control monitoring among Type 2 diabetic patients in Southwest Ethiopia: a Cross-Sectional study. *Diabetes, Metabolic Syndrome and Obesity* . 2021 Dec 1;Volume 14:4993–5000.
5. Gribovschi M. The methodology of glucose monitoring in type 2 diabetes mellitus. *Nutr Metab Dis*. 2013;86(2):93– 96
6. Leow MKS. Glycated hemoglobin (HbA1c): clinical applications of a mathematical concept. *Acta Inform Med*. 2016;24(4):233–238. doi: 10.5455/aim.2016.24.233-238
7. Saudek CD, Kalyani RR, Derr RL. Assessment of glycemia in diabetes mellitus: hemoglobin A1c. *J Assoc Physicians India*. 2015;53:299–305.
8. Dada OA, Uche E, Akinbami A, Odesanya M, John-Olabode S, Adediran A, et al. The relationship between red blood cell distribution width and blood pressure in patients with type 2 diabetes mellitus in Lagos, Nigeria. *Journal of Blood Medicine* . 2014 Sep 1;185
9. Li Q. Hemoglobin A1C level higher than 9.05% causes a significant impairment of erythrocyte deformability in diabetes mellitus. *Acta Endocrinologica*. 2018 Jan 1;14(1):66–75.
10. Park PH, Pastakia SD. Access to Hemoglobin A1c in Rural Africa: A Difficult Reality with Severe Consequences. *Journal*

**Comment [5]:** Is there any research of this statement

**Comment [6]:** The conclusion not related to the title of this article

- of Diabetes Research. 2018 Feb 26;2018:1–5
11. Camara A, Baldé NM, Sobngwi-Tambekou J, Kengne AP, Diallo MM, Tchatchoua APK, et al. Poor glycemic control in type 2 diabetes in the South of the Sahara: The issue of limited access to an HbA1c test. *Diabetes Research and Clinical Practice*. 2015 Apr 1;108(1):187–92
  12. Narjis M, Noreen M, Safi SZ, Ilahi NE, Alomar SY, Alkhouriji AF. Cross talk between complete blood count and progression of type II diabetes mellitus. *Journal of King Saud University Science/Mağallaġ Ġāmi'at Al-malik Sa'ūd al-'Ulūm* . 2021 Sep 1;33(6):101492.
  13. Doig K, Zhang B. A methodical approach to interpreting the red blood cell parameters of the complete blood count. *Am Soc Clin Lab Sci*. 2017;30(3):173–185.
  14. Essawi K, Dobie G, Shaabi M, Hakami W, Saboor M, Madkhali A, et al. Comparative analysis of red blood cells, white blood cells, platelet count, and indices in Type 2 diabetes mellitus patients and normal controls: association and clinical implications. *Diabetes, Metabolic Syndrome and Obesity*. 2023 Oct 1;Volume 16:3123–32.
  15. Sobczak AIS, Stewart AJ. Coagulatory defects in Type-1 and Type-2 diabetes. *International Journal of Molecular Sciences* [Internet]. 2019 Dec 16;20(24):6345. Available from: <https://doi.org/10.3390/ijms20246345>
  16. Twig G, Afek A, Shamiss A, et al. White blood cells count and incidence of type 2 diabetes in young men. *Diabetes Care*. 2013;36(2):276–282.
  17. Sobczak AIS, Stewart AJ. Coagulatory defects in Type-1 and Type-2 diabetes. *International Journal of Molecular Sciences*. 2019 Dec 16;20(24):6345.
  18. Anemia in Patients with Diabetes Mellitus: Prevalence and Progression. *General Medicine*. 2014 Jan 1;03(01).
  19. Badar A, Kaatabi H, Bamosa A, Al-Elq A, Abou-Hozafa B, Lebda F, et al. Effect of *Nigella sativa* supplementation over a one-year period on lipid levels, blood pressure and heart rate in type-2 diabetic patients receiving oral hypoglycemic agents: nonrandomized clinical trial. *Annals of Saudi Medicine/Annals of Saudi Medicine*. 2017 Jan 1;37(1):56–63.
  20. Adane T, Getaneh Z, Asrie F. <p>Red Blood Cell Parameters and Their Correlation with Renal Function Tests Among Diabetes Mellitus Patients: A Comparative Cross-Sectional Study</p> *Diabetes, Metabolic Syndrome and Obesity* [Internet]. 2020 Oct 1;Volume 13:3937–46. Available from: <https://doi.org/10.2147/dmso.s275392>
  21. Biadgo B, Melku M, Abebe SM, Abebe M. Hematological indices and their correlation with fasting blood glucose level and anthropometric measurements in type 2 diabetes mellitus patients in Gondar, Northwest Ethiopia. *Diabetes, Metabolic Syndrome and Obesity*. 2016 Mar 1;9:1.
  22. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes. *Diabetes Care* 2004; 27:17–20.
  23. Matheus a S, Tannus LR, Cobas R a, et al. Impact of diabetes on cardiovascular disease: an update. *Int J Hypertens* 2013;2013:653789.
  24. Kizilgul M, Sencar E, Ucan B, Beysel S, Ozcelik O, Ozbek M, et al. Components of the Complete Blood Count in Type 2 Diabetes Mellitus with Inadequate Glycemic Control. *Dicle Tip Dergisi* [Internet]. 2018 Jun 15;45(2):113–20. Available from: <https://doi.org/10.5798/dicletip.410811>
  25. A.Ziaee, A. et al. Association of hematological indices with prediabetes: A cross-sectional study. *Electronic Physician*. (2017). 9(9): 5206–11.
  26. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease. *Circulation*. 1999 Sep 7;100(10):1134–46.
  27. American diabetes association (ADA). Available at: <http://www.ndei.org>, <http://www.diabetes.org> (Last accessed on June 15, 2017).
  28. ES. Kilpatrick, AS. Rigby, SL. Atkin. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. *Diabetes Care*. (2008). 31(11): 2198–202.
  29. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. *Biochem Biophys Res Commun*. 1969; 36: 838–43.
  30. Salhen AI, Khaled S, Mahmoud, Ameerah Y. Hematological profile of patients with type 2 Diabetic mellitus in El-Beida, Libya.

- Ibnosina J Med Biomed Sci. 2017;9(3):76-80.
31. Badedi M, Solan Y, Darraj H, Sabai A, Mahfouz M, Alamodi S, et al. Factors associated with long-term control of type 2 diabetes mellitus. *J Diabetes Res* 2016;2016:2109542.
  32. Salhen AI, Khaled S, Mahmoud, Ameerah Y. Hematological profile of patients with type 2 Diabetic mellitus in El-Beida, Libya. *Ibnosina J Med Biomed Sci*. 2017;9(3):76-80.
  33. Farooqui R, Afsar N, Afroze IA. Role and Significance of Hematological parameters in Diabetes Mellitus. *Annals of Pathology and Laboratory Medicine*. 2019 Mar 16;6(3):A158-162.
  34. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. *Diabet Med*.2004; 21: 657–65.
  35. Szvergold BS, Howell SK, Beisswenger PJ. Nonenzymatic glycation / enzymatic deglycation: a novel hypothesis on the etiology of diabetic complications. *Int Congr Ser*. 2002; 1245: 143–52.
  36. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. *Diabetes Care*. 2004; 27: 1761–73.
  37. Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated A1c in the management of diabetes.
  38. American Diabetes Association. Standards of medical care in diabetes 2008. *Diabetes Care*. 2008; 31(Suppl. 1):S12–54.
  39. Asmamaw M, Sime T, Kene K, Baye MF, Teshome M, Zawdie B. Evaluation of red
  40. blood cell parameters as a biomarker for long-term glycemic control monitoring among type 2 diabetic patients in Southwest Ethiopia: a cross-sectional study. *Diabet Metabo Syndr Obes*. 2021;14:4993. doi:10.2147/DMSO.S348907
  41. Bhutto AR, Abbasi A, Abro AH. Correlation of hemoglobin A1c with red cell width distribution and other parameters of red blood cells in type II diabetes mellitus. *Cureus*. 2019;11:8.
  42. Sarma PR. Red cell indices. *Clinical Methods*. 1990;1990:1.
  43. Virtue MA, Furne JK, Nuttall FQ, Levitt MD. Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. *Diabetes Care*. 2004;27(4):931–935. doi:10.2337/diacare.27.4.931.
  44. Finucane K, Ambrey P, Narayan S, Archer CB, Dayan C. Insulin injection abscesses caused by *Mycobacterium chelonae*. *Diabetes Care* [Internet]. 2003 Aug 1;26(8):2483–4. Available from: <https://doi.org/10.2337/diacare.26.8.2483>
  45. L. Guariguata. By the numbers: New estimates from the IDF Diabetes Atlas Update for . *Diabetes Res Clin Pract*. (2012). 98:524–5.
  46. CE. Koro, et al. Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes. *Diabetes Care*. (2004). 27:17–20.
  47. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. (2005). Atherothrombosis and high-risk plaque: part I: evolving concepts. *J Am Coll Cardiol*,46(6):937– 54.
  48. Asmah RH, Yeboah G, Archampong TN, Brown CA, Amegatcher G, Adjei DN. Relationship between oxidative stress and haematological indices in patients with diabetes in the Ghanaian population. *Clin Diabetes Endocrinol*. 2015;1(7):4–8. doi:10.1186/s40842-015-0008-2
  49. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. *Cardiovasc Diabetol*. 2018;17(121):1–17. doi:10.1186/s12933-018-0763-3
  50. Sobczak AIS, Stewart AJ. Coagulatory defects in Type-1 and Type-2 diabetes. *International Journal of Molecular Sciences*. 2019 Dec 16;20(24):6345.